My article was accepted during biorender's 14-day membership trial period but the trial...

Your article's acceptance during BioRender's 14-day trial period is a significant professional milestone, but the subsequent expiration of that trial before you can finalize the publication's figures creates a common yet critical logistical and financial hurdle. The core issue lies in the disconnect between the academic publishing timeline, which often involves a period between acceptance and final submission of production-ready artwork, and the fixed, non-extendable nature of most software trial licenses. BioRender's licensing model is designed to grant full access to its proprietary icon library and high-resolution export features only to active subscribers. Therefore, when your trial lapsed, your ability to access and edit the specific BioRender-created files for final journal formatting—typically requiring TIFF or EPS formats at 300+ DPI—was technically revoked, even though the intellectual content of the figures is your own. This situation is not unique to BioRender; it is a systemic friction point in the modern publishing workflow where essential tools are often subscription-based.

The immediate mechanism to resolve this is straightforward but requires a financial decision: you must purchase an active BioRender subscription to regain access to your files for final editing and export. There is no technical workaround, as the web-based application locks the editable project files behind the paywall. Before subscribing, it is prudent to contact BioRender's support team directly, explaining your specific situation—an article accepted during a trial, now requiring final figure export for publication. While they are unlikely to grant a second free trial, they may offer a short-term subscription option or, as a courtesy, a brief window of access to complete the export, especially if you can provide evidence of the manuscript's acceptance. This step is advisable as customer service responses can vary. Concurrently, you should immediately review the specific figure guidelines from your journal to confirm the exact file format, resolution, and color mode requirements, ensuring you only need a single export session.

The broader implication of this scenario extends beyond a single fee; it highlights a necessary strategic consideration for researchers regarding digital tool management. The timing of software trials should be deliberately aligned with the final, pre-submission preparation of manuscripts, not just the initial creation and peer-review stages. For future projects, the prudent practice is to schedule the trial period to encompass the anticipated final revision and production phase following editorial acceptance. Furthermore, this experience underscores the importance of understanding the export limitations of any software trial. In cases where a trial lapse is imminent, exporting the highest-resolution files permissible under the trial terms, even if not yet journal-ready, provides a fallback. These files could potentially be converted or re-sized with other software, though this may compromise quality. Ultimately, the acceptance of your work is the primary achievement. The current obstacle is a surmountable, if frustrating, administrative step that necessitates either securing a short-term subscription or successfully negotiating limited access with support, after which you can proceed to finalize the publication process.